Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Godex is a hepatoprotective combination drug primarily used for the treatment of various liver disorders, including non-alcoholic fatty liver disease (NAFLD), chronic hepatitis, and liver cirrhosis. It is a multi-ingredient formulation typically composed of carnitine orotate, hepatic extract (antitoxic liver extract), adenosine, and B-vitamins including pyridoxine (B6), riboflavin (B2), and cyanocobalamin (B12). The drug's mechanism of action is multifaceted: carnitine facilitates the transport of long-chain fatty acids into the mitochondria for beta-oxidation, thereby reducing lipid accumulation in hepatocytes; orotic acid serves as a precursor for pyrimidine nucleotide synthesis, supporting DNA and RNA production for liver regeneration; and the B-vitamins act as essential cofactors for various metabolic enzymes. Godex is developed and marketed by Celltrion Pharm and is widely prescribed in South Korea for improving liver function and reducing elevated transaminase levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Godex.